Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05036291 · ClinicalTrials.gov registry record · Phase 1
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Ningbo Newbay Technology Development Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT05036291: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Ningbo Newbay Technology Development Co..
NCT05036291 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Ningbo Newbay Technology Development Co.. The registered enrollment target is 120 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (37% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05036291, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Ningbo Newbay Technology Development Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors
Primary Outcome
Dose-limiting toxicities will be reviewed as a subset of adverse events that occurs within the first 28 days of dosing and meet protocol-specified criteria.
Conditions Studied
Interventions
- DRUG NB004 tablets
Study Locations (4)
Taiwan
- National Cheng Kung University Hospital（NCKUH） - Tainan
- National Taiwan University Hospital Yunlin Branch - Yunlin
Louisiana
- LSU-LCMC Health Cancer Center - New Orleans
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 1 |
What NCT05036291 shows while recruiting
NCT05036291 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which NB004 tablets is the first listed.
NCT05036291 reports a single indexed study location in Taiwan, Louisiana, Texas.
Frequently Asked Questions
What is clinical trial NCT05036291 about?
NCT05036291 is a clinical study titled "A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors". This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors
What is the current status of trial NCT05036291?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2021-10-01. Estimated completion is 2026-09-01.
What conditions does trial NCT05036291 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05036291?
The interventions under investigation include: NB004 tablets (DRUG).
Who is sponsoring clinical trial NCT05036291?
This trial is sponsored by Ningbo Newbay Technology Development Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05036291 being conducted?
This trial has 4 study locations across Louisiana, Texas, Taiwan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05036291's enrollment target sits among peer trials
120 104th of 189 higher than 85 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI